Wang Qi-Jing, Wang Hui, Pan Ke, Li Yong-Qiang, Huang Li-Xi, Chen Shi-Ping, He Jia, Ke Miao-La, Zhao Jing-Jing, Li Jian-Jun, Sun Jian-Cong, Liang Xiao-Ting, Ma Hai-Qing, Chen Yi-Bing, Xia Jian-Chuan
State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong 510060, PR China.
Chin J Cancer. 2010 Jul;29(7):641-8. doi: 10.5732/cjc.009.10772.
Cytokine-induced killer (CIK) cells and autologous dendritic cells-CIK (DC-CIK) cells co-cultured with autologous dendritic cells (DCs) and CIK cells are commonly used for immunotherapy recently. We compared the anti-tumor immune response of CIK cells, autologous DC-CIK cells, and semi-allogeneic DC-CIK cells to explore a more effective anti-tumor adoptive immunotherapy approach.
Peripheral monocytes were isolated from patients with renal carcinoma, lung cancer, or maxillary squamous cell carcinoma and their healthy adult children. Isolated cells were cultured and induced as DCs and CIK cells in vitro. CIK cells from patients were co-cultured with autologous DCs and DCs from their children respectively, generating DC-CIK cells and semi-allogeneic DC-CIK cells. The anti-tumor activities of autologous CIK cells, autologous DC-CIK cells, and semi-allogeneic DC-CIK cells were measured by LDH assay. Intracellular staining was used to test the secretion of cytokines. Flow cytometry was applied for detecting the phonotype changes of these three types of cells. Cell proliferation and cell apoptosis were detected by 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) and Annexin V/PI respectively.
Compared with autologous CIK cells and DC-CIK cells, semi-allogeneic DC-CIK cells significantly enhanced the anti-tumor activity and IFN-gamma secretion, reduced IL-4 secretion, increased the ratio of CD3(+)CD56(+) cells and CD3(+)CD8(+) cells, decreased the number of CD4(+)CD25(+) cells, promoted cell proliferation, and lessened cell apoptosis.
Semi-allogeneic DC-CIK cells had a stronger anti-tumor effect than did autologous CIK cells and DC-CIK cells. Our results provided experimental evidence for clinical application of DC-CIK cells.
细胞因子诱导的杀伤细胞(CIK)以及与自体树突状细胞(DC)共培养的自体树突状细胞 - CIK(DC - CIK)细胞近来常用于免疫治疗。我们比较了CIK细胞、自体DC - CIK细胞和半同种异体DC - CIK细胞的抗肿瘤免疫反应,以探索一种更有效的抗肿瘤过继性免疫治疗方法。
从肾癌、肺癌或上颌鳞状细胞癌患者及其健康成年子女中分离外周血单核细胞。将分离的细胞在体外培养并诱导为DC和CIK细胞。患者的CIK细胞分别与自体DC以及其子女的DC共培养,生成DC - CIK细胞和半同种异体DC - CIK细胞。通过乳酸脱氢酶(LDH)测定法检测自体CIK细胞、自体DC - CIK细胞和半同种异体DC - CIK细胞的抗肿瘤活性。采用细胞内染色检测细胞因子的分泌。应用流式细胞术检测这三种细胞的表型变化。分别通过5,6 - 羧基荧光素二乙酸琥珀酰亚胺酯(CFSE)和膜联蛋白V/碘化丙啶(Annexin V/PI)检测细胞增殖和细胞凋亡。
与自体CIK细胞和DC - CIK细胞相比,半同种异体DC - CIK细胞显著增强了抗肿瘤活性和γ干扰素(IFN - γ)分泌,减少了白细胞介素 - 4(IL - 4)分泌,增加了CD3(+)CD56(+)细胞和CD3(+)CD8(+)细胞的比例,减少了CD4(+)CD25(+)细胞数量,促进了细胞增殖,并减少了细胞凋亡。
半同种异体DC - CIK细胞比自体CIK细胞和DC - CIK细胞具有更强的抗肿瘤作用。我们的结果为DC - CIK细胞的临床应用提供了实验依据。